Previously, he served as president and CEO of Epizyme from to Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research.
Lionel has over 18 years of managerial experience in strategic and organizational consultancy dedicated to the healthcare industry in three consulting companies: Lionel has managed more than consulting assignments on primary and specialty care products, biotechnology products, OTC brands as well as e-health solutions.
The perimeter of his interventions concentrates on France as well as European, International and Corporate headquarters and he interacts with key decision makers within the Healthcare industry.
Jordi has been working in the healthcare sector for more than 18 years. He is focused on strategic and change management issues and in the past years has been focused on new product launches and market access issues.
He started his career as a controller for a joint venture in India between Nippon Kokan and Spie Batignolles. Following this experience, he joined Bossard Consultants, a major consultancy firm where he spent 7 years. Her consultant activity is specialized in corporate, international and operational strategies, evolutions in business models and organizations, and the optimization of performance across the life science industry.
During the last twenty years, Christine Garnier has managed more than assignments on primary and specialty care products, vaccine products, as well as medical device and OTC. She accompanies executive committees and operational and functional management in the development of vision, their strategies and the evolution of their organizations.
The perimeters of her interventions concentrate on Europe and fast developing countries South East Asia, Latin America. She provides her clients with a strong expertise in strategy and organization coupled by her skill to identify and initiate necessary transformations. Before joining AEC Partners, Christine Garnier previously worked for 12 years in the pharmaceutical industry holding marketing positions in Wyeth and international marketing and strategic planning at Rhone Poulenc Rorer.
He has over 17 years experience consulting in the pharmaceutical and medical device industries, particularly focused on the development of market access strategies for products in early stage of development and ready for marketing-authorization applications.
His regular interactions and negotiations with French health authorities are a key asset that help him achieve client objectives and optimize the rebates and conditions linked to the requested level of price. JF's interventions are focused on France and Europe where he has built a network of experts sharing the same skills and that work together on bottom-up approaches to generate operational and pragmatic market access strategies.
Nerea Alonso Partner Graduated in Business Administration in Barcelona Spainshe has more than 15 years of experience in the healthcare sector.
Nerea has broad and transversal experience in national and international projects for the biopharmaceutical and medical devices industries covering most business and therapeutic areas. She started her career in the health sector with AEC Partners in and has recently joined back to develop the Spanish Market.
His continuing involvement with some of the largest financial institutions has offered him the opportunity to closely observe the emergence of Fintech. Philippe has integrated Connected Health to the HTI practice with a number of assignments in the field of remote monitoring for chronic and post-acute care.
He was one of the founders of AEC Partners in and has been active in its development as a Partner since Rodolphe supports his consulting activities with his business and hands-on former experience in corporate finance and the drug industry.
SinceRodolphe has been leading strategic, organizational and business development consulting assignments for many healthcare clients from startups to Big Pharma, from biological to OTC drugs, vaccines, diagnostics and other medical devices.
He also worked for drug supply chain players, healthcare service providers, healthcare professional organizations, and investment funds interested in healthcare and life sciences.
He has extensive experience with both French-based and international firms. His analytical skills coupled with strategic visioning and business planning make him a solid advisor and enable his clients to rely on strategic recommendations able to deliver clear vision to their associates.
Tina has worked on a diverse range of subjects but her areas of expertise are linked to strategy definition and implementation, as well as product launch preparation and organization effectiveness. Sandrine has developed methodologies and tools adapted to the context of more than missions she has managed in various healthcare companies.
She is responsible for the partnership between AEC Partners and Orange Consulting which defines digital solutions to address strategic and organizational challenges for our clients.
SPYRO MOUSSES, PHD Chief Executive Officer. Dr. Mousses is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more. Business Planning Analyst Novartis. March – Present 9 months. Croatia. Junior BPA & Finance Operations Novartis. December – March 1 year 4 months. Ana Kruljac. Business Planning Analyst at Novartis. Novartis. University of Zagreb/Sveuciliste u Title: Business Planning Analyst at .
Sandrine is French and works in English and French. Thomas Joudinaud Partner M. BetweenThomas practiced as a cardiac surgeon in the Bichat academic hospital, Paris. This followed his medical training and specialization in cardiovascular and thoracic surgery in France and the US.
At BCG he specialized in the Healthcare sector private and public providers, pharmaceuticals, Medtech and medical associations — pro bonoworking on more than 35 projects around strategy definition, due diligence, operation excellence, turn around and Post Merger Integration PMI.
Nicolas has extensive experience in pharmaceutical, animal health, medical devices and vaccines industries. He held various operational positions at St Jude Medical France: Daniel Teper Partner Dr.The 6th Microbiome R&D and Business Collaboration Forum is one of the three meetings forming the Microbiome Probiotics Series: Europe.
The series will bring together more than industry, academic, and investment leaders to discuss the must cutting-edge microbiome research, challenges and opportunities in moving research towards commercialisation, and potential partnerships and. Corporate structure. Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group.
Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations.
Gain free stock research access to stock picks, stock . Kim is an experienced scientist with entrepreneurial and business management experience in cell therapy.
She spent the last 10 years at Lonza, developing a services business, including tissue acquisition, process development, bioassays and related services to support GMP manufacturing of cellular therapeutics.
Eli Lilly & Co. stock price, stock quotes and financial overviews from MarketWatch. Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more. Voluntis innovates healthcare solutions by embedding connectivity in therapeutics and medical intelligence in software.
GE’s business is fundamentally about people—great people, operating safely and with the highest standards of integrity and environmental protection, set our Company apart.
SPYRO MOUSSES, PHD Chief Executive Officer. Dr. Mousses is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development.